Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus

Journal of Hospital Infection

Volumn 53, Issue 1, 2003, Pages 58-63

  Nakamura, T ^a   Ushiyama, C ^a   Suzuki, Y ^a   Inoue, T ^b   Shoji, H ^c   Shimada, N ^d   Koide, Hikaru ^d  

^a Misato Junshin Hospital   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Toray Medical Company   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Endotoxin; MRSA; PMX F; Teicoplanin

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFMETAZOLE; ENDOTOXIN; FOSFOMYCIN SODIUM; HABEKACIN; IMMUNOGLOBULIN; METICILLIN; POLYMYXIN B; TEICOPLANIN; VASOACTIVE AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; HEMOPERFUSION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SEPSIS; SURVIVAL RATE;

ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; ENDOTOXINS; FEMALE; HEMOPERFUSION; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; POLYMYXIN B; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; TREATMENT OUTCOME;

EID: 0346142713     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhin.2002.1332     Document Type: Article

References (26)

1. Martin, C, Viviand, X, Leone, M, & Thirion, X (2000). Effect of norepinephrine on the outcome of septic shock. Crit Care Med, 28 2758-2765.
2. Opal, SM, & Cohen, J (1999). Clinical Gram-positive sepsis: does it fundamentally differ from Gram-negative bacterial sepsis?. Crit Care Med, 27 1608-1616.
3. Bone, RC (1994). Gram-positive organisms and sepsis. Arch Intern Med, 154 26-34.
4. Kodama, M, Tani, T, & Hanasawa, K et al. (1997). The PMX Clinical Study Group. Treatment of sepsis by plasma endotoxin removal: hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res, 4 293-300.
5. Shoji, H, Tani, T, Hanasawa, K, & Kodama, M (1998). Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge. Designing and antiendo-toxin efficacy in the clinical application. Therapeut Apheresis, 2 3-12.
6. Nakamura, T, Ebihara, I, & Shimada, N et al. (1998). Effects of haemoperfusion with polymyxin B-immobilized fibre on serum neopterine and soluble interleukin-2 receptor concentrations in patients with septic shock. J Infect, 37 241-247.
7. Nakamura, T, Ebihara, I, Shimada, N, & Koide, H (1998). Changes in plasma erythropoietin and interleukin-6 concentrations in patients with septic shock after hemoperfusion with polymyxin B-immobilized fiber. Int Care Med, 24 1272-1276.
8. Bantar, C, Durlach, R, & Nicola, F et al. (1999). Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphlococcus aureus infections. J Antimicrob Chemother, 43 737-740.
9. De Lalla, F, Viola, R, Pellizzer, G, Lazzarini, L, Tramarin, A, & Fabris, P (2000). Regional prophylaxis with teicoplanin in monolateral or bilateral total knee replacement: an open study. Antimicrob Agents Chemother, 44 316-319.
10. Rolston, KV I, Chow, AW, & Bodey, GP (1999). Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by Gram-positive pathogens. J Infect Chemother, 5 108-112.
11. Bone, RC, Balk, RA, & Cerra, FB et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 101 1644-1655.
12. Knaus, WA, Draper, EA, Wagner, EP, & Zimmermann, GJ (1985). APACHE II: A severity of disease classification system. Crit Care Med, 13 818-829.
13. Timmerman, CP, Mattsson, E, & Martinez-Martinez, L et al. (1993). Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun, 61 4167-4172.
14. Hurley, JC (1994). Concordance of endotoxemia with Gram-negative bacteremia in patients with Gram-negative sepsis: a meta-analysis. J Clin Microbiol, 32 2120-2127.
15. Stegmayr, BG (2001). Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Therapeut Apheresis, 5 123-127.
16. Yoshida, T, & Hiramatsu, K (1993). Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus. Microbial Immunol, 37 853-859.
17. Jaber, BL, Barrett, TW, Cendoroglo Neto, M, Sundaram, S, King, AJ, & Pereira, BJ (1998). Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge. ASAIO J, 44 48-53.
18. Iwama, H, & Komatsu, T (1998). Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from Gram-positive infection. Acta Anaesthesiol Scand, 42 1-4.
19. Schlievert, PM (1981). Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic endotoxin type C. Infect Immunol, 26 123-128.
20. Miwa, K, Fukuyama, M, Kunitomo, T, & Igarashi, H (1994). Rapid assay for detection of toxic shock syndrome toxin-1 from human sera. J Clin Microbiol, 32 539-542.
21. Otsuka, Y, Yoshibe, T, Namioka, M, & Ezaki, T (2000). Combination effect of teicoplanin and beta-lactams on MRSA. Jpn J Antibiot, 53 643-651.
22. Wilson, AP R, & Gruneberg, RN (1994). Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis, 13 701-710.
23. Davis, RL, Smith, AL, & Koup, JR (1986). The red man syndrome and slow infusion of vancomycin. Ann Intern Med, 104 285-286.
24. Babul, N, & Pasko, M (1988). Teicoplanin: a new glycopeptide antibiotic complex. Drug Intelligence Clin Pharm, 22 218-226.
25. Knapp, S, Thalhammer, F, & Locker, GJ et al. (1998). Prognostic value of MIP-1-alpha, TGF-beta, sELAM-1, and sVCAM-1 in patients with Gram-positive sepsis. Clin Immunol Immunopathol, 87 139-144.
26. Yoh, K, Kobayashi, M, & Yamaguchi, N et al. (2000). Cytokines and T-cell responses in superantigen-related glomerulonephritis following methicillin-resistant Staphylococcus aureus infection. Nephrol Dial Transplant, 15 1170-1174.